A phase 3 multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eneboparatide (AZP-3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)

• Protocol code: AZP-3601-CLI-002
• EudraCT code: _
• Research group: Diabetes and Metabolism
• Service: Endocrinology
• Principal investigator:  Fidilio Meli, Enzamaría
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase III
• Status: Recruiting volunteers